VALSARTAN

Background Information:

Valsartan is a potent, selective and orally active AT1 receptor
antagonist (Ki = 2.38 nM), with over 30,000-fold selectivity over AT2
receptors. It is an investigational antihypertensive drug being studied
for use in combination with AHU-377 (molar ratio: 1:1) (Our Prod No.
CT-AHU377). The combination drug, known as LCZ696, is in clinical trials
for the treatment of heart failure.

Reference:

1. L. Criscione, et al, Pharmacological profile of Valsartan: a
potent, orally active, nonpeptide antagonist of the angiotensin II
AT1-receptor subtype, Br J Pharmacol, 1993, Oct; 110(2):761-71.
2. S. Hanafy, et al, Effects of angiotensin II blockade on
inflammation-induced alterations of pharmacokinetics and
pharmacodynamics of calcium channel blockers, Br J Pharmacol, 2008 Jan;
153(1):90-9.
3. A. A. Voors, et al., The potential role of valsartan + AHU377 (
LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs.
2013 Aug. 22(8):1041-7.

APIM050349: VALSARTAN

CAS No.: 137862-53-4.
Molecular Formula: C₂₄H₂₉N₅O_3.
Molecular Weight: 435.5.
Purity: >99% (HPLC at 214 and 254 nm).
QC: HPLC-MS, ¹HNMR.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.